ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Drug toxicity"

  • Abstract Number: 1214 • ACR Convergence 2024

    All-Cause Mortality in Patients with Chronic Musculoskeletal Pain Using Pregabalin or Duloxetine: A Retrospective Cohort Study in US Veterans

    Sachalee Campbell1, Laura L. Daniel2, Alyson L. Dickson3, Otis Wilson3, C. Michael Stein3, Puran Nepal4, Adriana M. Hung5 and Cecilia P. Chung2, 1University of Miami/ Jackson Health System, Miami, FL, 2University of Miami, Miami, FL, 3Vanderbilt University Medical Center, Nashville, TN, 4Vanderbilt University Medical Center, Vanderbilt, TN, 5Veterans Administration Tennessee Valley Healthcare System, Nashville, TN

    Background/Purpose: Musculoskeletal pain affects more than 10% of the general population. Recent trends in managing chronic musculoskeletal pain have favored non-opioid analgesics, for example, pregabalin,…
  • Abstract Number: 2503 • ACR Convergence 2024

    Hypothalamic-Pituitary-Adrenal Axis Suppression by Prednisolone Reversed by the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Clofutriben

    Frank S Czerwiec1, Irina Bancos2, Paul M Stewart3, Ketan Desai1 and David A Katz1, 1Sparrow Pharmaceuticals, Portland, OR, 2Mayo Clinic, Rochester, MN, 3University of Leeds, Leeds, United Kingdom

    Background/Purpose: Approximately 1% of the population rely on chronic glucocorticoid (GC) prescription to control autoimmune and inflammatory conditions. Risk of GC induced adrenal insufficiency (GC-AI)…
  • Abstract Number: 0299 • ACR Convergence 2024

    Real-World Tolerability of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease

    Saloni Goyal, Briana DiSilvio and Joanna Marco, Allegheny Health Network, Pittsburgh, PA

    Background/Purpose: Nintedanib is an antifibrotic medication used to treat interstitial lung disease (ILD), including connective tissue disease-associated ILD (CTD-ILD). Clinical trials that led to its…
  • Abstract Number: 1215 • ACR Convergence 2024

    Mortality in US Veterans with Musculoskeletal Conditions Using Cyclobenzaprine or Baclofen

    Maria Intriago1, Puran Nepal2, Laura L. Daniel1, Alyson L. Dickson3, Otis Wilson3, C. Michael Stein3, Adriana M. Hung4 and Cecilia P. Chung1, 1University of Miami, Miami, FL, 2Vanderbilt University Medical Center, Vanderbilt, TN, 3Vanderbilt University Medical Center, Nashville, TN, 4Veterans Administration Tennessee Valley Healthcare System, Nashville, TN

    Background/Purpose: Cyclobenzaprine is a commonly-used centrally-acting muscle relaxant; it has been approved for short-term treatment of muscle spasms associated with acute musculoskeletal pain despite limited…
  • Abstract Number: 0337 • ACR Convergence 2024

    Characterization of Statin Induced Myopathy in the Hospital Setting

    Olivia Yang1, KUMAR VENKAT2, Jeffery Durbin3 and Scott Kubomoto1, 1Riverside Community Hospital, Riverside, CA, 2Voluntary Clinical Associate Professor of Medicine -UCRSOM, Riverside, California, IRVINE, CA, 3HCA Healthcare Physicians Services Group, Brentwood, TN

    Background/Purpose: Adverse effects of statin use involve the muscle and related rhabdomyolysis. Known risk factors for rhabdomyolysis include female sex, older age, Asian race, hypothyroidism,…
  • Abstract Number: 1243 • ACR Convergence 2024

    A Patient-Focused Program for Using Steroids Wisely

    John Stone1, Michelle Petri2, Jeffrey Gelfand3, Camille Kotton4, Jane McDowell5, George Papaliodis6, meredith Marinaro7, Matt Wilkinson8, Walter Lentfert9 and Martha Stone10, 1Massachusetts General Hospital , Harvard Medical School, Concord, MA, 2Johns Hopkins University School of Medicine, Timonium, MD, 3University of California, San Francisco, San Francisco, CA, 4Harvard Medical School, Boston, MA, 5Queens University Belfast, Belfast, Ireland, 6Massachusetts General Hospital, Boston, MA, 7Novartis, Hartford, CT, 8UpThereEverywhere, London, United Kingdom, 9UpThereEverywhere, Wilmington, NC, 10Steritas, LLC, CONCORD, MA

    Background/Purpose: Patients have no comprehensive, curated resource on steroid use to facilitate effective collaboration in their own care. Consequently, truly shared decision making around steroid…
  • Abstract Number: 0363 • ACR Convergence 2024

    Comparative Risk of Demyelinating Diseases Among Patients on TNF-Alpha Inhibitors: A Cohort Study Using the TriNetX Database

    Rafal Ali1, Yurilu Gonzalez Moret2, Roua Hussein3 and Fabian Rodriguez4, 1Jefferson Einstein Philadelphia, Lansdale, PA, 2Jefferson Einstein Philadelphia, Philadelphia, PA, 3Al-Mustansiriyah University/ college of medicine, New York, NY, 4Jefferson Einstein Hospital, Philadelphia, PA

    Background/Purpose: TNF-alpha inhibitors are widely used in the field of rheumatology and have been linked to various possible adverse events, including demyelinating diseases. This association…
  • Abstract Number: 1949 • ACR Convergence 2024

    Implementation of Pharmacist-Led Comprehensive Medication Management for Puerto Ricans with Rheumatic Diseases

    Ileana Rodriguez Nazario, Kyle Melin and Luis Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR

    Background/Purpose: Comprehensive Medication Management (CMM) is a standardized intervention provided by clinical pharmacists that uses subjective and objective patient information to create a plan to…
  • Abstract Number: 0376 • ACR Convergence 2024

    Preliminary Results of the Ondansetron Pre-medication Trial in Juvenile Idiopathic Arthritis: A Pragmatic Randomized Controlled Trial Nested in the CAPRI Registry

    Gaelle Chedeville1, Heinrike Schmeling2, Jean-Philippe Proulx-Gauthier3, Michelle Batthish4, Jean Jacques De Bruycker5, Brian Feldman6, Roberta A Berard7, Roxana Bolaria8, Amieleena Chhabra9, Lily Lim10, Adam Huber11, Matthew Berkowitz12, Thomas Loughin12 and Jaime Guzman13, and CAPRI Registry Investigators, 1The Montreal Children's Hospital, Montreal, QC, Canada, 2University of Calgary, Calgary, AB, Canada, 3CHU de Quebec - Universite Laval, Quebec, QC, Canada, 4McMaster Children's Hospital, Hamilton, ON, Canada, 5UNIVERSITY OF MONTREAL, Montreal, QC, Montreal, QC, Canada, 6Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 7London Health Sciences Centre, London, ON, Canada, 8Victoria Arthritis Center, Victoria, BC, Canada, 9University of British Columbia, Penticton, BC, Canada, 10University of Manitoba, Winnipeg, MB, Canada, 11IWK Health Centre, Halifax, NS, Canada, 12Simon Fraser University, Burnaby, BC, Canada, 13University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada

    Background/Purpose: About 50% of children with Juvenile Idiopathic Arthritis (JIA) receiving methotrexate (MTX) develop MTX intolerance with severe anticipatory nausea/vomiting and avoidance behaviors. Intolerance often…
  • Abstract Number: 1986 • ACR Convergence 2024

    Disease Flare Following Immune Checkpoint Inhibition in Patients with Cancer and Preexisting Vasculitis

    Juan Sevillano1, Yixuan Zhou2, Juan Ruiz3, Noha Abdel-Wahab4 and Maria Suarez-Almazor1, 1MD Anderson Cancer Center, Houston, TX, 2Baylor College of Medicine, Houston, 3MD Anderson, Houston, TX, 4University of Texas MD Anderson Cancer Center, houston, TX

    Background/Purpose: Immune checkpoint inhibitors (ICI) are effective therapies for patients with cancer, but they often cause immune-related adverse events (irAE). There is limited data on…
  • Abstract Number: 0439 • ACR Convergence 2024

    Contraception Counseling and Contraception Use Among SLE and RA/JIA Patients at a Public Medical Center in Los Angeles: Investigating Teratogenic Medication Use and Language Preferences

    Laura Kobashigawa1, Cassidy Hernandez-Tamayo2, Katherine Ruddy3, Melissa Wilson2 and Leanna Wise4, 1University of Southern California/Los Angeles General Medical Center, Pasadena, CA, 2Keck School of Medicine of USC, Los Angeles, CA, 3University of Southern California/ Los Angeles General Medical Center, Los Angeles, CA, 4LAC+USC/Keck Medicine of USC, Pasadena, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)/juvenile idiopathic arthritis (JIA) frequently impact women of reproductive age. Management of these patients is particularly important…
  • Abstract Number: 1997 • ACR Convergence 2024

    Features of interleukin-1 and interleukin-6 Inhibitor (IL-1i/IL-6i) Related Severe Delayed Adverse Reactions in Subjects with or Without Reaction-risk Associated HLA-DRB1*15

    Vivian E Saper1, Kazutoyo Osoegawa1, Ruud Verstegen2, Marcelo A Fernandez Vina1 and Lu Tian1, and Drug Hypersensitivity Consortium, 1Stanford University, Stanford, CA, 2The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: A very serious drug-related adverse event is reported with inhibitors of IL-1 and IL-6 (IL-1i/IL6i). This reaction scores as drug reaction with eosinophilia and…
  • Abstract Number: 0441 • ACR Convergence 2024

    A Qualitative Improvement Project to Incorporate the Mycophenolate Risk Evaluation and Mitigation Strategies in an Academic Lupus Clinic

    Dahima Cintron1, Jennifer Rogers2, Rebecca Sadun1, Mithu Maheswaranathan3, Kai Sun1, Jayanth Doss1, Lisa Criscione-Schreiber3 and Megan Clowse4, 1Duke University, Durham, NC, 2Duke, Durham, NC, 3Duke University School of Medicine, Durham, NC, 4Duke University, Chapel Hill, NC

    Background/Purpose: Mycophenolate Mofetil/Mycophenolic acid (MMF) is an immunosuppressant used to treat SLE. Due to the teratogenic effects of MMF, the FDA recommended universal risk evaluation…
  • Abstract Number: 2000 • ACR Convergence 2024

    Induction of Systemic Inflammatory Diseases with Dupilumab Therapy

    Jeanne Tisseau des Escotais1, Camille Taille2, Julie Merindol3, Matthieu Groh4, Perrine SMETS5, Amel Boudjemaa6, Alexandra Audemard7, Nabil Belfeki8, Philippe Bonniaud9, Chloe Comarmond10, Isabelle DELACROIX11, Charlotte Descours12, Lucile Grange13, Paul Legendre14, Nihal Martis15, Thomas Moulinet16, Béatrice Walls17, Laurent Chouchana1 and Benjamin Terrier18, 1Cochin, Paris, France, 2Bichat Hospital, Paris, France, 3Internal Medicine Department, University Hospital of Nice, Côte d'Azur University, Nice, Provence-Alpes-Côte d'Azur, France., Nice, France, 4Foch, Suresnes, France, 5Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, 6CHU créteil, Créteil, France, 7Tours, Tours, France, 8CH Melun, Melun, France, 9Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, 10Lariboisière University Hospital, Paris, France, 11CHI créteil, Créteil, France, 12CH Tours, Tours, France, 13CH Saint-Etienne, Saint-Etienne, France, 14Service Médecine Interne et Polyvalente, Centre Hospitaliers Le Mans, Le Mans, France, 15CH Nice, Nice, France, 16CHRU de Nancy, Vandœuvre-lès-Nancy, France, 17Paris, Paris, France, 18Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: Dupilumab is a monoclonal antibody directed against the alpha subunit of the interleukin (IL)-4 receptor, blocking interleukin (IL)-4 and IL-13 signaling. It is approved…
  • Abstract Number: 0537 • ACR Convergence 2024

    Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk

    Knkush Hakobyan1, Talar Acob2, Mesrop Aleksanyan3, Tigran Kakhktsyan3, Omar Jumaah3 and Sajina Prabhakaran4, 1Capital Health medical center, Princeton, NJ, 2College of medicine-university of Baghdad, Plainsboro Township, NJ, 3Capital Health Medical Center, Trenton, 4Capital health Rheumatology specialists, Newtown, PA

    Background/Purpose: Janus kinase (JAK) inhibitors have been widely used in treatingrheumatological conditions like rheumatoid arthritis and psoriatic arthritis. Despite theirefficacy, there are concerns regarding major…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology